Prostate Cancer News - 2018-02
General News
About prostate cancer research, cases and public awareness:- Prostatepedia Weekly 2.9.18
- Genitourinary Cancers Symposium |: Translating Evidence to Multidisciplinary Care
Case Management
Planning a campaign against prostate cancer:- What to do first for men with mCRPC | THE "NEW" PROSTATE CANCER INFOLINK: The currently "great unanswered" question in the management of advanced prostate cancer is the order of agents to be used in the treatment of men who are receiving first-line therapy for metastatic prostate cancer after it becomes castration-resistant. …
Life Choices
can influence the odds in your favor:- nothing new yet
Diet
can starve the cancer- nothing new yet
Exercise
can give you strength to fight the cancer and treatment side effects
- nothing new yet
Screening and Diagnosis
early detection is important because symptoms appear too late for treatment:- nothing new yet
Biopsies and Pathology
Genomics
Tests
Imaging
- 18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study: Aim To prospectively evaluate the clinical impact and the diagnostic performance of FCH-PET/CT in patients with occult biochemical recurrence of prostate cancer (PCa). . Conclusion FCH PET/CT is a powerful tool to localise the sites of occult biochemical recurrence of PCa, leading to an adequat
- Technique of Multiparametric MR Imaging of the Prostate - Radiologic Clinics
- Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making - Radiologic Clinics
- Prognostic value of [18F]-fluoromethylcholine PET/CT Before Stereotactic Body Radiotherapy For Oligometastatic Prostate Cancer - International Journal of Radiation Oncology • Biology • Physics
Treatment
Active Surveillance AS
- Yearly Biopsy Not Needed for Prostate Cancer Surveillance
- MR Imaging for Prostate Cancer Screening and Active Surveillance - Radiologic Clinics
Surgery RP
frequently the first choice for localized PCa, robotic assist dominates:- nothing new yet
Radiation RT
- nothing new yet
Hormone ADT
- nothing new yet
Chemo
- nothing new yet
Immunotherapy
- Promise of novel combinations in CRPC | Biotech Strategy Blog: A look at targeted therapies and immunotherapies in advanced prostate cancer and where future directions might lie with novel combination approaches in development/
New Techniques
- Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer - De Laere - 2018 - The Prostate - Wiley Online Library
- Two Drugs Offer Hope Against a Tough-to-Treat Prostate Cancer: Two cancer drugs can stall the progression of a particularly hard-to-treat form of prostate cancer, a pair of new trials shows.
- Apalutamide delays spread of certain prostate cancers in trial | Cancer Research UK: An experimental hormone therapy delays the spread of prostate cancer that has stopped responding to standard treatment, according to new clinical trial results.
- FDA Approves Abiraterone/Prednisone for Metastatic Prostate Cancer | Cancer Network | The Oncology Journal: The US Food and Drug Administration has approved abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic prostate cancer patients with high-risk, castration-sensitive disease. 1
Side Effects
- nothing new yet
Advanced/Recurrence
- What to Know About Advanced Prostate Cancer: Advanced prostate cancer is an often-misunderstood description of later-stage prostate cancer. Learn how it is diagnosed and how it can be treated.
- Time to Metastasis Prolonged in Castration-Resistant Prostate Ca | Medpage Today: Researchers found a 22-month improvement with enzalutamide
- The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study - Shou - 2018 - The Prostate - Wiley Online Library
No comments:
Post a Comment